DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
CD109 Drives Stemness and Chemoresistance in Colorectal Cancer via LRRC8A/AKAP12/PKCα-Mediated STAT3 Activation and WNT Signaling
Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide, with a poor survival rate at the metastatic stage. Here, we identify CD109-a negative regulator of TGFβ signaling-as a key driver of stemness and drug resistance through modulation of Wnt signaling in advanced CRC. CD109 expression strongly correlates with TGFβ levels in patient tumors and is enriched in the aggressive CRIS-B subtype, where it associates with poor clinical outcome. CD109 silencing reduced STAT3 phosphorylation and cell proliferation, without affecting migration or invasion. Moreover, global expression analysis revealed downregulation of various hallmarks of cancer stemness (i.e. LGR5 expression), together with increased TGFβ signaling and cellular senescence. Mechanistically, CD109 interacts with LRRC8A, a subunit of the volume-regulated anion channel (VRAC), which associates with AKAP12 to activate PKCα and promote STAT3 phosphorylation. This CD109/LRRC8A/AKAP12/PKCα axis sustains Wnt signaling, stemness, and drug resistance. Consistently, co-expression of CD109/LRRC8A/AKAP12 correlates with poor prognosis in CRC patients. Genetic or pharmacological disruption of this CD109/LRRC8A/AKAP12/PKCα axis impaired STAT3 signaling, reduced LGR5 expression and Wnt signaling, and sensitized cells to chemotherapy. In vivo, CD109 or LRRC8A knockdown significantly impaired liver homing and metastatic colonization in mouse models, showing stronger effects in Swiss nude mice than in highly immunodeficient NSG mice. Collectively, these findings support CD109 as a central regulator for STAT3-driven stemness and chemoresistance in advanced CRC, via the LRRC8A/AKAP12/PKCα axis, and highlight its potential value as a therapeutic target in metastatic disease., PON was supported by a Juan de la Cierva
contract from the Ministry of Science, Innovation and
Universities (MICIU) (Spain). IB and MC were
supported by IND2022/BMD-23554 and IND2024/
BMD-34329 fellowship grants of the Comunidad de
Madrid. AMC was funded by a PhD fellowship
Ramon Areces (BTVP25S22277). JMFF´s lab was
funded by the Spanish Ministry of Science and
Innovation (MCIN)/State Research Agency (AEI,
Agencia Estatal de Investigación)/10.13039/
501100011033/, and FEDER Funds (Fondo Europeo
de Desarrollo Regional) (grant PID2022-136546OB-I00
to J.M.F-F); “Unidad de Excelencia María de Maeztu”
CEX2024-001431-M, funded by MICIU/AEI/
10.13039/501100011033. AO’s lab was supported by
projects CNS2022-135134 and PID2021-125656OB-I00
financed by MICIU/AEI/10.13039/501100011033,
10.13039/501100011033 and by project SenesceX
S2022/BMD-7393 financed by the Comunidad de
Madrid. JIC´s lab was supported by grants PID2021-
122227OB-I00 and PID2024-156301OB-I00 (MICIU)
with funds MCIN/AEI/10.13039/501100011033 and
“Next-Generation EU”/PRTR, and grant
S2022/BMD-7212 funded by the Comunidad de
Madrid (Spain). Ethics approval and consent to participate
The collection of patient-derived samples for, Peer reviewed, Modelo experimental animal, Modelo experimental alternativo-NAM, Mamíferos - Roedores, in silico, in vitro - Tipos celulares - líneas inmortalizadas humanas, in vitro - Sistemas de cultivo - Cultivos 3D - organoides
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-136546OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 CEX2024-001431-M
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2024-2027 CNS2022-135134
,
AEI PID2021-125656OB-I00
,
AEI PID2021-122227OB-I00
,
AEI PID2024-156301OB-I00